Lintuzumab-gelonin conjugate

Drug Profile

Lintuzumab-gelonin conjugate

Alternative Names: Anti-CD-33 Immunotoxin Hum-195/rGel; Anti-CD33 monoclonal antibody M195-gelonin conjugate; Gelonin-lintuzumab conjugate; Hum-195/rGel; HuM195/rGel; Monoclonal antibody M195-gelonin conjugate

Latest Information Update: 20 Jul 2012

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action CD33 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 08 Oct 2010 Lintuzumab-gelonin conjugate is still in phase I trials for Myeloid leukaemia in USA
  • 30 Jun 1999 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)
  • 30 Jun 1999 Phase-I clinical trials in Myelodysplastic syndromes in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top